Sanofi’s Efdoralprin Alfa Shows Superiority in Phase 2 Study for Alpha-1 Antitrypsin Deficiency Emphysema
I'm PortAI, I can summarize articles.
Sanofi's efdoralprin alfa has received orphan designation from the EMA for treating AATD-related emphysema. The drug showed superiority in a Phase 2 study, meeting all primary and key secondary endpoints compared to standard plasma-derived therapy. Results will be presented at an upcoming medical meeting. The drug is still in clinical development, with safety and efficacy not yet evaluated by regulatory authorities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments